XORTX Therapeutics Inc. (XRTX)
NASDAQ: XRTX · Real-Time Price · USD
0.4000
+0.0050 (1.27%)
Mar 23, 2026, 8:25 AM EDT - Market open
Company Description
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada.
It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney.
The company is based in Calgary, Canada.
XORTX Therapeutics Inc.
| Country | Canada |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Allen Davidoff |
Contact Details
Address: 3710 - 33rd Street NW Calgary, AB T2L 2M1 Canada | |
| Phone | 403-455-7727 |
| Website | xortx.com |
Stock Details
| Ticker Symbol | XRTX |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001729214 |
| CUSIP Number | 98420Q207 |
| ISIN Number | CA98420Q3061 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, Chief Executive Officer, President and Director |
| Dr. Michael Scott Bumby D.V.M., M.B.A. | Chief Financial Officer |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer |
| Nick Rigopoulos | Director of Communications |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations |
| Charlotte May | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 19, 2026 | 6-K | Report of foreign issuer |
| Mar 13, 2026 | 6-K | Report of foreign issuer |
| Mar 5, 2026 | 6-K | Report of foreign issuer |
| Mar 3, 2026 | 6-K | Report of foreign issuer |
| Feb 27, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | EFFECT | Notice of Effectiveness |
| Feb 13, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Feb 5, 2026 | 6-K | Report of foreign issuer |
| Jan 2, 2026 | 6-K | Report of foreign issuer |